BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24155887)

  • 1. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome.
    Matito A; Morgado JM; Álvarez-Twose I; Sánchez-Muñoz L; Pedreira CE; Jara-Acevedo M; Teodosio C; Sánchez-López P; Fernández-Núñez E; Moreno-Borque R; García-Montero A; Orfao A; Escribano L
    PLoS One; 2013; 8(10):e76116. PubMed ID: 24155887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
    Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
    Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
    Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
    J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.
    Garcia-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Teodosio C; Sanchez-Muñoz L; Muñiz C; Muñoz-Gonzalez JI; Mayado A; Matito A; Caldas C; Morgado JM; Escribano L; Orfao A
    Blood; 2016 Feb; 127(6):761-8. PubMed ID: 26622064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
    Bonadonna P; Perbellini O; Passalacqua G; Caruso B; Colarossi S; Dal Fior D; Castellani L; Bonetto C; Frattini F; Dama A; Martinelli G; Chilosi M; Senna G; Pizzolo G; Zanotti R
    J Allergy Clin Immunol; 2009 Mar; 123(3):680-6. PubMed ID: 19135713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
    Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
    Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.
    Mayado A; Teodosio C; Garcia-Montero AC; Matito A; Rodriguez-Caballero A; Morgado JM; Muñiz C; Jara-Acevedo M; Álvarez-Twose I; Sanchez-Muñoz L; Matarraz S; Caldas C; Muñoz-González JI; Escribano L; Orfao A
    Leukemia; 2016 Jan; 30(1):124-30. PubMed ID: 26153655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
    Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
    Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.